0001127602-20-025120.txt : 20200915 0001127602-20-025120.hdr.sgml : 20200915 20200915170004 ACCESSION NUMBER: 0001127602-20-025120 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200914 FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zaks Tal Zvi CENTRAL INDEX KEY: 0001690927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 201176572 MAIL ADDRESS: STREET 1: 122 BELLEVUE STREET CITY: NEWTON STATE: MA ZIP: 02458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-09-14 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2020-09-14 4 M 0 10000 20.93 A 10000 D Common Stock 2020-09-14 4 M 0 34 14.22 A 10034 D Common Stock 2020-09-14 4 M 0 10000 19.15 A 20034 D Common Stock 2020-09-14 4 S 0 2082 60.86 D 17952 D Common Stock 2020-09-14 4 S 0 2574 61.85 D 15378 D Common Stock 2020-09-14 4 S 0 10210 62.79 D 5168 D Common Stock 2020-09-14 4 S 0 5168 63.53 D 0 D Stock Option (Right to Buy) 20.93 2020-09-14 4 M 0 10000 0 D 2020-03-08 2029-03-08 Common Stock 10000 229195 D Stock Option (Right to Buy) 14.22 2020-09-14 4 M 0 34 0 D 2028-02-28 Common Stock 34 60209 D Stock Option (Right to Buy) 19.15 2020-09-14 4 M 0 10000 0 D 2026-08-10 Common Stock 10000 134790 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.15 to $61.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.24 to $63.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.25 to $63.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. This option is fully vested and exercisable. /s/ Lori Henderson, as Attorney-in-Fact 2020-09-15